NVCT:NASDAQ, Nuvectis Pharma, Inc.
NVCT stock overview
Nuvectis Pharma, Inc. (NVCT:NASDAQ) closed at $19.39 on November 20, 2026,
down 2.27% on the day.
The stock trades 33.8% below its 52-week high of $29.28
and 236.0% above its 52-week low of $5.77.
Over the past year, it gained 223.7%.
Nuvectis Pharma, Inc. is part of the Health Care sector.
Key figures
- Price
- $19.39
- Day change
- -2.27%
- Volume
- 301,603
- Average volume
- 204,734
- Market cap
- 666M+
- 52-week range
- $5.77 – $29.28
- 50-day average
- $20.30
- 200-day average
- $15.41
Price action over the past year
In 252 trading sessions since November 20, 2025, NVCT closed higher on 139 days (55%).
Its best day was June 24, 2026 (+39.49%) and its worst was June 30, 2026 (-35.54%).
The stock moved 10% or more in a single session 11 times.
Recent signals
NVCT news
-
Nov 4, 2026:
Nuvectis Pharma, Inc. Q3 2026 Earnings Call Summary
-
Nov 4, 2026:
Nuvectis Pharma Inc (NVCT) (Q3 2026) Earnings Call Highlights: Late-Stage Transformation, $140 ...
-
Nov 4, 2026:
Nuvectis Pharma Q3 Earnings Call Highlights
-
Nov 4, 2026:
Nuvectis (NVCT) Q3 2026 Earnings Call Transcript
-
Nov 4, 2026:
Nuvectis Pharma Reports Third Quarter 2026 Financial Results and Business Highlights
-
Nov 3, 2026:
Nuvectis Faces A Spending Test As Wall Street Expects A Sharply Narrower Loss
-
Nov 2, 2026:
Nuvectis Pharma to Report Third Quarter 2026 Financial Results on November 4, 2026
-
Oct 26, 2026:
Nuvectis Reports Complete Brain Tumor Responses as Big Pharma Pays Billions for Cancer Drugs (NASDAQ: NVCT)
About Nuvectis Pharma, Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. Its pipeline products include NXP800, NXP900.
Similar stocks
Find more stocks like NVCT with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.